Accelerating Clinical Trials in the EU: publication of 2022-2026 workplan
August 30, 2022
The European Commission (EC), the Heads of Medicines Agencies (HMA) and the European Medicines Agency (EMA) have published the 2022-2026 workplan of the Accelerate Clinical Trials in the EU (ACT EU) initiative. The workplan has been prepared based on the recommendations of the European medicines agencies network strategy to 2025 and the European Commission’s Pharmaceutical Strategy for Europe.
The initiative launched in January just before the Clinical Trials Regulation (CTR) became applicable and seeks to promote the development of high-quality, safe and effective medicines by strengthening the European clinical trials environment. The workplan is structured in line with the ten priority actions of ACT EU and highlights key focus areas, such as innovation in clinical trials, robust methodologies, and collaboration across stakeholders.
To find out more please click here for the joint press release on ACT EU.